Developer docs
API playgroundTry for free, no card

Search company profiles

Predicine

Full company profile

uuid0005ojr

Namestring
Predicine
Legal namestring
Predicine, Inc.
Websiteurl
predicine.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Predicine is a private molecular diagnostics company founded in 2015 and headquartered in Hayward, California, with 101-250 employees and a stated workforce composition of approximately 35% PhDs. The company develops liquid biopsy–based genomic profiling assays for cancer diagnostics, treatment selection, monitoring, and minimal residual disease (MRD) detection, serving two primary customer bases: biopharmaceutical companies (for biomarker-driven clinical trial support and companion diagnostic co-development) and licensed physicians/healthcare providers (for clinical diagnostic testing).

Its core technology is the proprietary GeneRADAR platform, which performs simultaneous cell-free DNA (cfDNA) and cell-free RNA (cfRNA) profiling from a single blood or urine sample, paired with the DeepSEA bioinformatics pipeline that uses proprietary analytical methods to suppress sequencing/PCR error and call variants at ultra-sensitive levels (down to 5 PPM for MRD and as little as 0.4 mL of plasma input). The commercial product portfolio includes PredicineBEACON (personalized MRD), PredicineATLAS (600-gene pan-cancer panel), PredicineCARE (200-gene treatment selection assay under FDA PMA review), PredicineRNA (88-gene fusion/splicing panel), PredicineHEME (259-gene hematologic panel), PredicineWES+ (exome sequencing), and PredicineHEREDITARY (25-gene germline assay), supplemented by add-on modules (PredicineCARE Ultra, PredicineALERT, PredicineSCORE).

Predicine monetizes through (i) fee-for-service clinical laboratory testing performed in its CAP/CLIA-certified labs (5 facilities across Hayward CA, Houston TX, Schaumburg IL, and Shanghai), (ii) biopharma professional services contracts spanning biomarker discovery through Phase I-III clinical trial support, and (iii) a future companion diagnostic licensing/royalty stream contingent on FDA approval of PredicineCARE (PMA module submitted September 2025; Breakthrough Device Designation granted 2022). Go-to-market is enterprise field sales to biopharma combined with physician-driven test ordering, scientific conference presence (ASCO, AACR, ASCO GU), peer-reviewed publication strategy, and regional distribution partners (zakara, daladria, CellDiagnostics, sciencewerke). Pricing is not publicly disclosed.

Short descriptiontext

Predicine is a molecular diagnostics company that develops liquid biopsy genomic profiling assays for cancer treatment selection, monitoring, and MRD detection, serving biopharmaceutical companies, physicians, and academic researchers through CAP/CLIA-certified labs in the US and China.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersHayward, United States
HQ citystring
Hayward
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
liquid biopsy diagnostics, cancer genomic profiling, next-generation sequencing, companion diagnostics, minimal residual disease monitoring
Industry2 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code4 codes
  • Medical and Diagnostic Laboratories6215
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Molecular Diagnostics / Liquid Biopsy Cancer Genomics
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Clinical Laboratory Testing Services
TypeSubscription Recurring
Description

Predicine generates revenue through providing CLIA-certified genomic profiling tests for cancer diagnostics. Tests are performed in their CAP/CLIA certified laboratories in the US and China, with turnaround times of 6-14 days depending on the assay.

predicine.com
2Biopharma Clinical Trial Support Services
TypeProfessional Services
Description

Predicine partners with biopharmaceutical companies to support biomarker-driven drug development, from target discovery through CDx development and commercial launch. Services include comprehensive genomic profiling for clinical trials and companion diagnostic co-development.

predicine.com
3Companion Diagnostic Development
TypeLicensing Royalties
Description

Predicine is pursuing FDA premarket approval for PredicineCARE as a companion diagnostic for bladder cancer. This regulatory pathway could enable co-development partnerships with pharmaceutical companies for companion diagnostics with novel therapeutics.

clpmag.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1Laboratory developed tests with CLIA certification
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing information not publicly available. Orders placed through physician ordering form on website.

predicine.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 10 records shown
1PredicineCARE
Description

200-gene CLIA-certified cfDNA assay for treatment selection in cancer patients

predicine.com
+9 more records
Core offering1 text field

Predicine develops and delivers liquid biopsy-based cancer genomic profiling services and assays through its proprietary GeneRADAR wet-lab platform and DeepSEA bioinformatics pipeline, run from CLIA/CAP-certified labs in the United States and China. Its portfolio includes tumor profiling, MRD monitoring, whole-exome, RNA, hereditary, and hematologic cancer assays sold to biopharmaceutical companies for clinical development and to oncologists for treatment-decision support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Ultra-sensitive MRD detection down to 5 PPM with PredicineBEACON
+3 more records
Product overview1 text field

Predicine is a molecular insight company offering a portfolio of comprehensive genomic profiling assays for precision medicine development. The core offering centers on the GeneRADAR™ liquid biopsy platform that analyzes cell-free DNA (cfDNA) and RNA (cfRNA) from blood or urine samples. The product portfolio includes: PredicineBEACON™ (MRD detection), PredicineATLAS™ (600-gene pan-cancer panel), PredicineCARE™ (200-gene treatment selection panel), PredicineRNA™ (88-gene fusion/splicing panel), PredicineHEME™ (259-gene hematologic malignancies panel), PredicineWES+™ (whole exome sequencing), and PredicineHEREDITARY™ (25-gene hereditary cancer panel). Supporting these is the DeepSEA™ bioinformatics platform for ultra-sensitive variant detection. The company provides end-to-end biopharma clinical research services including biomarker discovery, companion diagnostic co-development, and global clinical trial support across US and China laboratories.

Product and service1 record
1PredicineBEACON
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Leading commercial liquid biopsy company offering Guardant360 (ctDNA), Guardant Reveal (MRD), and biopharma CDx services. Directly comparable to Predicine across oncology liquid biopsy, MRD, and pharma trial support.

TypeDirect peer
Description

Molecular diagnostics company with Signatera MRD assay and oncology-focused liquid biopsy products. Comparable in MRD sensitivity claims, biopharma trial support, and clinical lab services model.

TypeDirect peer
Description

Genomics company offering NeXT Personal (tumor-informed MRD) and ImmunoID Next platform for biopharma. Closely comparable as a smaller, science-driven liquid biopsy competitor targeting biopharma CDx and oncology trials.

TypeDirect peer
Description

Molecular profiling company offering MI Profile, MI Cancer Seek, and biopharma discovery services. Comparable as a multi-omic profiling competitor serving biopharma and oncology clinicians with proprietary assays.

5Tempus AI
TypeDirect peer
Description

Precision medicine company combining NGS profiling (xT, xR) with AI/data analytics for biopharma and providers. Comparable in multi-modal genomic profiling and biopharma clinical trial support services.

TypeBroad incumbent
Description

Roche subsidiary offering FoundationOne CDx (FDA-approved tissue NGS) and FoundationOne Liquid CDx. The dominant FDA-approved oncology CDx; broader portfolio but directly competes in liquid biopsy and pharma CDx partnerships.

TypeBroad incumbent
Description

Public diagnostics company with Oncotype, Cologuard, and the recently acquired TheraomiQ liquid biopsy franchise. Comparable as a multi-product oncology diagnostics competitor with biopharma services.

TypeBroad incumbent
Description

Oncology-focused clinical lab services company offering comprehensive genomic profiling and biopharma trial support. Comparable as a competing oncology reference lab with biopharma/biotech services business.

TypeRegional player
Description

China-based liquid biopsy company offering NGS-based cancer panels (e.g., CanPatrol) and pharma services. Directly comparable in product category and is a primary China-region competitor for cross-border trial work.

TypeBroad incumbent
Description

Life sciences tools and diagnostics company that acquired Resolution Bioscience for liquid biopsy NGS. Comparable through its cancer genomics business serving biopharma and clinical research customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Predicine

Molecular Diagnostics / Liquid Biopsy Cancer Genomicspredicine.com

Predicine is a molecular diagnostics company that develops liquid biopsy genomic profiling assays for cancer treatment selection, monitoring, and MRD detection, serving biopharmaceutical companies, physicians, and academic researchers through CAP/CLIA-certified labs in the US and China.

What Predicine does

Predicine is a private molecular diagnostics company founded in 2015 and headquartered in Hayward, California, with 101-250 employees and a stated workforce composition of approximately 35% PhDs. The company develops liquid biopsy–based genomic profiling assays for cancer diagnostics, treatment selection, monitoring, and minimal residual disease (MRD) detection, serving two primary customer bases: biopharmaceutical companies (for biomarker-driven clinical trial support and companion diagnostic co-development) and licensed physicians/healthcare providers (for clinical diagnostic testing).

Its core technology is the proprietary GeneRADAR platform, which performs simultaneous cell-free DNA (cfDNA) and cell-free RNA (cfRNA) profiling from a single blood or urine sample, paired with the DeepSEA bioinformatics pipeline that uses proprietary analytical methods to suppress sequencing/PCR error and call variants at ultra-sensitive levels (down to 5 PPM for MRD and as little as 0.4 mL of plasma input). The commercial product portfolio includes PredicineBEACON (personalized MRD), PredicineATLAS (600-gene pan-cancer panel), PredicineCARE (200-gene treatment selection assay under FDA PMA review), PredicineRNA (88-gene fusion/splicing panel), PredicineHEME (259-gene hematologic panel), PredicineWES+ (exome sequencing), and PredicineHEREDITARY (25-gene germline assay), supplemented by add-on modules (PredicineCARE Ultra, PredicineALERT, PredicineSCORE).

Predicine monetizes through (i) fee-for-service clinical laboratory testing performed in its CAP/CLIA-certified labs (5 facilities across Hayward CA, Houston TX, Schaumburg IL, and Shanghai), (ii) biopharma professional services contracts spanning biomarker discovery through Phase I-III clinical trial support, and (iii) a future companion diagnostic licensing/royalty stream contingent on FDA approval of PredicineCARE (PMA module submitted September 2025; Breakthrough Device Designation granted 2022). Go-to-market is enterprise field sales to biopharma combined with physician-driven test ordering, scientific conference presence (ASCO, AACR, ASCO GU), peer-reviewed publication strategy, and regional distribution partners (zakara, daladria, CellDiagnostics, sciencewerke). Pricing is not publicly disclosed.

Predicine firmographics

Firmographics
Name
Predicine
Legal name
Predicine, Inc.
Website
https://predicine.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
Predicine is a molecular diagnostics company that develops liquid biopsy genomic profiling assays for cancer treatment selection, monitoring, and MRD detection, serving biopharmaceutical companies, physicians, and academic researchers through CAP/CLIA-certified labs in the US and China.
Ownership category
akta.pro rank

Predicine industry classification

Industry
Product category
Molecular Diagnostics / Liquid Biopsy Cancer Genomics
NAICS
Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Liquid biopsy diagnostics
  • Cancer genomic profiling
  • Next-generation sequencing
  • Companion diagnostics
  • Minimal residual disease monitoring

Where Predicine is headquartered

Location

Headquarters

HQ city
Hayward
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Predicine business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Clinical Laboratory Testing Services: Predicine generates revenue through providing CLIA-certified genomic profiling tests for cancer diagnostics. Tests are performed in their CAP/CLIA certified laboratories in the US and China, with turnaround times of 6-14 days depending on the assay.
  2. Biopharma Clinical Trial Support Services: Predicine partners with biopharmaceutical companies to support biomarker-driven drug development, from target discovery through CDx development and commercial launch. Services include comprehensive genomic profiling for clinical trials and companion diagnostic co-development.
  3. Companion Diagnostic Development: Predicine is pursuing FDA premarket approval for PredicineCARE as a companion diagnostic for bladder cancer. This regulatory pathway could enable co-development partnerships with pharmaceutical companies for companion diagnostics with novel therapeutics.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goLaboratory developed tests with CLIA certification

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Predicine product offering

Product offering

Core offering

Predicine develops and delivers liquid biopsy-based cancer genomic profiling services and assays through its proprietary GeneRADAR wet-lab platform and DeepSEA bioinformatics pipeline, run from CLIA/CAP-certified labs in the United States and China. Its portfolio includes tumor profiling, MRD monitoring, whole-exome, RNA, hereditary, and hematologic cancer assays sold to biopharmaceutical companies for clinical development and to oncologists for treatment-decision support.

Product overview

Predicine is a molecular insight company offering a portfolio of comprehensive genomic profiling assays for precision medicine development. The core offering centers on the GeneRADAR™ liquid biopsy platform that analyzes cell-free DNA (cfDNA) and RNA (cfRNA) from blood or urine samples. The product portfolio includes: PredicineBEACON™ (MRD detection), PredicineATLAS™ (600-gene pan-cancer panel), PredicineCARE™ (200-gene treatment selection panel), PredicineRNA™ (88-gene fusion/splicing panel), PredicineHEME™ (259-gene hematologic malignancies panel), PredicineWES+™ (whole exome sequencing), and PredicineHEREDITARY™ (25-gene hereditary cancer panel). Supporting these is the DeepSEA™ bioinformatics platform for ultra-sensitive variant detection. The company provides end-to-end biopharma clinical research services including biomarker discovery, companion diagnostic co-development, and global clinical trial support across US and China laboratories.

Differentiator

Problem solved

Functional benefit

Brands

  • PredicineCARE: 200-gene CLIA-certified cfDNA assay for treatment selection in cancer patients
  • PredicineATLAS
  • PredicineBEACON
  • PredicineRNA
  • PredicineHEME
  • PredicineWES+
  • PredicineHEREDITARY
  • GeneRADAR
  • DeepSEA
  • Generadar

Products and services

  • PredicineBEACON

Quantifiable outcome

  • Ultra-sensitive MRD detection down to 5 PPM with PredicineBEACON
  • +3 more outcomes

Companies that use Predicine

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Predicine technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Predicine partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Predicine competitors and assessment

Company assessment

Direct peers

  • Guardant Health: Leading commercial liquid biopsy company offering Guardant360 (ctDNA), Guardant Reveal (MRD), and biopharma CDx services. Directly comparable to Predicine across oncology liquid biopsy, MRD, and pharma trial support.
  • Natera: Molecular diagnostics company with Signatera MRD assay and oncology-focused liquid biopsy products. Comparable in MRD sensitivity claims, biopharma trial support, and clinical lab services model.
  • Personalis: Genomics company offering NeXT Personal (tumor-informed MRD) and ImmunoID Next platform for biopharma. Closely comparable as a smaller, science-driven liquid biopsy competitor targeting biopharma CDx and oncology trials.
  • Caris Life Sciences: Molecular profiling company offering MI Profile, MI Cancer Seek, and biopharma discovery services. Comparable as a multi-omic profiling competitor serving biopharma and oncology clinicians with proprietary assays.
  • Tempus AI: Precision medicine company combining NGS profiling (xT, xR) with AI/data analytics for biopharma and providers. Comparable in multi-modal genomic profiling and biopharma clinical trial support services.

Broad incumbents

  • Foundation Medicine: Roche subsidiary offering FoundationOne CDx (FDA-approved tissue NGS) and FoundationOne Liquid CDx. The dominant FDA-approved oncology CDx; broader portfolio but directly competes in liquid biopsy and pharma CDx partnerships.
  • Exact Sciences: Public diagnostics company with Oncotype, Cologuard, and the recently acquired TheraomiQ liquid biopsy franchise. Comparable as a multi-product oncology diagnostics competitor with biopharma services.
  • NeoGenomics: Oncology-focused clinical lab services company offering comprehensive genomic profiling and biopharma trial support. Comparable as a competing oncology reference lab with biopharma/biotech services business.
  • Agilent Technologies: Life sciences tools and diagnostics company that acquired Resolution Bioscience for liquid biopsy NGS. Comparable through its cancer genomics business serving biopharma and clinical research customers.

Regional players

  • Burning Rock Biotech: China-based liquid biopsy company offering NGS-based cancer panels (e.g., CanPatrol) and pharma services. Directly comparable in product category and is a primary China-region competitor for cross-border trial work.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Predicine social profiles

Digital presence

Predicine compliance and trust

Trust signal

Compliance6 records

Predicine financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Predicine leadership team

Management profile

Number of profiles

Profiles7 records

Predicine funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Predicine M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Predicine

What does Predicine do?

Predicine develops and delivers liquid biopsy-based cancer genomic profiling services and assays through its proprietary GeneRADAR wet-lab platform and DeepSEA bioinformatics pipeline, run from CLIA/CAP-certified labs in the United States and China. Its portfolio includes tumor profiling, MRD monitoring, whole-exome, RNA, hereditary, and hematologic cancer assays sold to biopharmaceutical companies for clinical development and to oncologists for treatment-decision support.

Is Predicine a public or private company?

Predicine is a private company. It is classified as venture growth investor backed and is currently operating.

When was Predicine founded?

Predicine was founded in 2015. It employs 51 to 100 people.

Where is Predicine based?

Predicine is headquartered in Hayward, United States, in the North America region.

How does Predicine make money?

Three revenue lines are on record. Clinical Laboratory Testing Services are the primary driver. The others are biopharma Clinical Trial Support Services and companion Diagnostic Development.

Who are Predicine's main competitors?

Direct peers on record are Guardant Health, Natera, Personalis, Caris Life Sciences and Tempus AI. Broad incumbents are Foundation Medicine, Exact Sciences, NeoGenomics and Agilent Technologies. Burning Rock Biotech is listed as a regional player.

Does Predicine have an API?

No public API is recorded for Predicine.

What industry is Predicine in?

Predicine's product category is Molecular Diagnostics / Liquid Biopsy Cancer Genomics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAAMAH, Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes). Its NAICS code is 6215 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
CuretodayPredicineCARE Urine Test Advances in FDA Review for Bladder CancerPredicine submitted the first module of its premarket approval application to the U.S. Food and Drug Administration for PredicineCARE, a urine-based next-generation sequencing assay intended as a companion diagnostic for bladder cancer. The test utilizes a capture-based method to detect genetic alterations in cell-free DNA with high precision, having previously received breakthrough device designation to expedite review. This submission lays the groundwork for future companion diagnostic developments using both blood- and tissue-based samples.Clinical Lab ProductsPredicine Submits First PMA Module to FDA for Bladder Cancer Companion DiagnosticPredicine Inc has submitted the first module of its premarket approval application to the FDA for PredicineCARE, a urine-based NGS assay for bladder cancer that received Breakthrough Device Designation in 2022. The initial module covers manufacturing and quality systems, with future modules to follow for additional indications. The company aims to validate a non-invasive diagnostic platform for cancer genomics globally.Urology TimesPremarket approval application initiated with FDA for companion diagnostic in bladder cancerPredicine, Inc. has initiated a premarket approval (PMA) application with the U.S. FDA for its PredicineCARE assay to be used as a companion diagnostic in bladder cancer. The company submitted the first module of the application, which includes documentation of its manufacturing and quality management systems, while further modules are planned following the completion of registrational trials. This development is supported by a collaboration with Janssen, a Johnson & Johnson company.GlobeNewswirePredicine announces six studies showcasing MRD and liquid biopsy innovations at ESMO 2023Predicine will present six poster studies at ESMO 2023 in Madrid, showcasing its liquid biopsy innovations including PredicineBEACON for MRD analysis and other cfDNA assays. The presentations cover urinary ctDNA monitoring, genomic profiling in breast and bladder cancer, and copy number detection. The company aims to reshape personalized cancer care and companion diagnostic development.UroTodayASCO GU 2024: Urine-Based Testing for Patient Selection and Genomic Characterization of Patients with FGFR Alteration-Positive NMIBC Treated with TAR-210Janssen partnered with Predicine to evaluate a urine-based diagnostic assay, PredicineCARE, for selecting patients with FGFR alteration-positive non-muscle-invasive bladder cancer (NMIBC) to receive the intravesical drug TAR-210. Preliminary results from a first-in-human clinical study presented at ASCO GU 2024 indicated that the urine assay successfully identified additional eligible patients and demonstrated strong recurrence-free and complete response rates among enrolled subjects.GlobeNewswirePredicine to Introduce PredicineALERT™ MRD Assay andPredicine will present two studies and introduce PredicineALERT MRD liquid biopsy for genitourinary cancers at the 2023 AUA Annual Meeting in Chicago. The assay offers tumor-naive methylation-based MRD detection with fast turn-around time and low sample input. The company is collaborating with biopharma partners on liquid biopsy studies for clinical trials and commercialization.GlobeNewswirePredicine to Introduce PredicineALERT™ MRD Assay and Present Twelve Posters at AACR 2023 ConferencePredicine announced at the 2023 AACR conference that it will present data from 12 studies and introduce PredicineALERT, a methylation-based minimal residual disease (MRD) liquid biopsy assay. The assay requires no personalized probe designs, offers fast turn-around times down to 6 days, and uses as little as 2.5ng of cell-free DNA.GlobeNewswirePredicine to Introduce PredicineCOMPLETE™, its Genome-Wide Liquid Biopsy Solution, at the Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingPredicine announced PredicineCOMPLETE, its genome-wide liquid biopsy solution, at the SITC 37th Annual Meeting in Boston. The solution provides genome-wide and epigenomic insights to support cancer research and clinical drug development. New data on Predicine's blood-based assays will be presented.GlobeNewswirePredicine Expands Its Nationwide COVID-19 Testing Capability Through the Recent FDA EUA Authorization of Predicine SARS-CoV-2 RT-PCR Test and Self-Collection KitPredicine received FDA EUA authorization for its SARS-CoV-2 RT-PCR test and self-collection kit, enabling nationwide COVID-19 testing expansion. The test delivers results in under six hours and detects variants including Omicron sub-variants. The company plans to use the authorization to increase community testing access.Clinical Lab ProductsPredicine Liquid Biopsy Outperforms in ctDNA Assay StudyPredicine announced that its PredicineATLAS liquid biopsy assay outperformed four other leading assays in a study led by Bristol Myers Squibb scientists, demonstrating superior sensitivity, specificity, and accuracy. The research highlighted the assay's ability to detect gene deletions and filter background noise without germline DNA controls, particularly at low DNA input levels. These findings provide a framework for evaluating liquid biopsy platforms for clinical implementation, patient testing, and companion diagnostics development.